Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors.

Authors

null

Suzanne I.M. Neppelenbroek

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands

Suzanne I.M. Neppelenbroek , Yvonne M. Geurts , Berthe M.P. Aleman , Cecile P.M. Janus , Saskia E Rademakers , Roel J. de Weijer , Richard W.M. Van Der Maazen , Josée M. Zijlstra , Max Beijert , Karijn M.S. Verschueren , Bastiaan Ta , Marten R. Nijziel , Eduardus F.M. Posthuma , Marie José Kersten , Karin Muller , Liane te Boome , Yavuz Bilgin , Eva de Jongh , Michael Schaapveld , Flora Van Leeuwen

Organizations

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands, Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, LUMC, Leiden, Netherlands, Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands, Radboud University Medical Center, Nijmegen, Netherlands, Department of Hematology, Amsterdam UMC location VUmc, Amsterdam, Netherlands, University Medical Center Groningen, Groningen, Netherlands, Department of Radiation Oncology, Instituut Verbeeten, Tilburg, Netherlands, Maastro Clinic, Maastricht, Netherlands, Catharina Cancer Institute, Department of Hemato-Oncology, Catharina Hospital, Eindhoven, Netherlands, Reinier de Graaf Gasthuis, Delft, Netherlands, Department of Hematology, Amsterdam UMC location AMC, Amsterdam, Netherlands, Radiotherapiegroep, Deventer, Netherlands, Haaglanden Medical Center, Den Haag, Netherlands, Department of Internal Medicine, Admiraal de Ruyter Hospital, Goes, Netherlands, Albert Schweitzer Hospital, Dordrecht, Netherlands

Research Funding

Other Foundation
KWF Dutch Cancer Society

Background: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Recently concern has been raised that anthracyclines may also increase BC risk, based on studies in childhood cancer survivors with/without a history of chest RT. So far, the association between anthracyclines and BC risk has not been examined in cancer survivors treated at adolescent/adult ages. Now that RT dose and volumes are decreasing, the potential contribution of anthracyclines to BC risk is an important issue. Methods: We assessed BC risk in a cohort of 2314 female 5-year HL survivors, treated at ages 15-50 years and diagnosed between 1965 and 2008 in 20 Dutch hospitals. Treatment factors were time-dependently included in the analysis, focusing on the effect of anthracycline exposure on BC risk. Results: After a median follow-up of 18.8 years, 258 women developed invasive BC or ductal carcinoma in situ as a subsequent malignancy. The 30-year cumulative incidence was 15.0% (95% Confidence Interval (CI) 12.8-17.4%). Mantle field RT (or other RT involving both axillae) was associated with increased risk of BC (Hazard ratio (HR) 1.9; 95% CI 1.2-2.8) compared to no supradiaphragmatic RT or RT to the neck only (Table 1). Gonadotoxic treatment (>4.2 g/m2 procarbazine or pelvic RT) significantly decreased this risk. In a multivariable analysis, anthracycline exposure was associated with increased BC risk (HR 1.8; 95% CI 1.3-2.5) in patients who received a cumulative dose of >200 mg/m2. Among patients exposed to gonadotoxic treatment, the HR of BC associated with >200mg/m2 anthracyclines was 3.8 (95% CI 2.0-7.2), with a trend for higher risk with higher anthracycline dose (HR 1.58 per 100mg/m2 anthracycline, p<0.001). Conclusions: Our results suggest an association of anthracyclines with BC risk in HL survivors. Also when accounting for the protective effect of gonadotoxic treatment on RT-associated BC risk, anthracyclines significantly contributed to a higher BC risk.

Cox PH regression model of anthracycline exposure and breast cancer risk.


Number of patients N=2314
Events (%) N=258
Hazard ratio (95% CI)
Anthracyclines



 No anthracyclines
994
172 (17.3%)
1.0
 35-200 mg/m2 (median: 150 mg/m2)
471
21 (4.5%)
1.5 (0.9-2.5)
 >200 mg/m2 (median: 245 mg/m2)
793
64 (8.1%)
1.8 (1.3-2.5)
 Unknown
56
1 (1.8%)
0.3 (0.0-2.0)
Supradiaphragmatic RT



 No supradiaphragmatic RT
356
20 (5.6%)
1.0
 Incomplete mantle field
968
48 (5.0%)
0.9 (0.5-1.5)
 Full mantle field
990
190 (19.2%)
1.9 (1.2-3.1)
Gonadotoxic therapy



 No procarbazine or pelvic RT
1213
160 (13.2%)
1.0
 No pelvic RT &<=4.2 g/m2 procarbazine
453
43 (9.5%)
0.8 (0.5-1.2)
 No pelvic RT &>4.2 and <8.4 g/m2 procarbazine
331
35 (10.6%)
0.7 (0.4-1.0)
 No pelvic RT &>=8.4 g/m2 procarbazine
124
9 (7.3%)
0.4 (0.2-0.9)
 Pelvic RT
193
11 (5.7%)
0.3 (0.1-0.6)

RT: radiotherapy; adjusted for age at first treatment.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Late and Long-Term Adverse Effects

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 12074)

DOI

10.1200/JCO.2021.39.15_suppl.12074

Abstract #

12074

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Georgina Virginia Whelan

First Author: Florence Lennie Wong

First Author: Lauren Victoria Ghazal